7 recruiting, 2 not yet recruiting, 1 unknown. 10 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Recruiting 7, Not yet recruiting 2, Unknown 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow CAPOX: new trials by email Literature Review of CAPOX trials Research Report on CAPOX
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer node-sparing modified short-course radiotherapy, standard short-course radiotherapy - Rectal Cancer | Phase 3 | Not yet recruiting | Sir Run Run Shaw Hospital | 210 | 2026-10-25 | 2026-10-28 |
| Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer Pucotenlimab combine with CAPOX, CAPOX - Rectal Cancer, pMMR (Microsatellite Stable Rectal Cancer) | Phase 3 | Recruiting | Sun Yat-sen University | 556 | 2026-04-20 | 2026-04-30 |
| Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer FOLFOXIRI, CAPOX, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) - Locally Advanced Rectal Carcinoma | Phase 3 | Recruiting | J. W. A. Burger | 394 | 2026-03-16 | 2026-10-27 |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) Pumitamig, Folfox, Capox - Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Bristol-Myers Squibb | 690 | 2026-03-13 | 2026-09-30 |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer Pumitamig, FOLFOX, FOLFIRI - Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2 / Phase 3 | Recruiting | Bristol-Myers Squibb | 990 | 2025-12-31 | 2026-10-23 |
| Pre-Operative Treatment in REseCTable COlon CanceR mFOLFOXIRI, mFOLFOX-6, CAPOX - Colo-rectal Cancer, Colon Cancer | Phase 3 | Not yet recruiting | Dominik Paul Modest | 714 | 2025-04-01 | 2025-03-28 |
| TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer SCRT, CAPOX, CAPOXIRI - Locally Advanced Rectal Cancer | Phase 3 | Recruiting | National Cancer Center Hospital East | 608 | 2022-11-21 | 2025-04-03 |
| Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) mFOLFOX6, mFOLFOXIRI, FOLFIRI - Colorectal Cancer | Phase 3 | Recruiting | Dominik Paul Modest | 507 | 2021-12-06 | 2025-12-12 |
| Induction Chemotherapy for Locally Recurrent Rectal Cancer Combination drug, Chemoradiotherapy, Surgery locally recurrent rectal cancer - Recurrent Rectal Cancer | Phase 3 | Recruiting | Catharina Ziekenhuis Eindhoven | 364 | 2020-11-13 | 2022-09-06 |
| Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer FOLFOX regimen, CAPOX - Colorectal Cancer | Phase 3 | Unknown | GERCOR - Multidisciplinary Oncology Cooperative Group | 2000 | 2009-05-12 | 2023-09-29 |
Colorectal Neoplasms (4) · Rectal Neoplasms (4) · Colonic Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Digestive System Neoplasms (1) · Gastrointestinal Neoplasms (1) · Intestinal Neoplasms (1) · Margins of Excision (1) · Pathologic Complete Response (1) · Stomach Neoplasms (1)
Bristol-Myers Squibb (2) · Dominik Paul Modest (2) · Catharina Ziekenhuis Eindhoven (1) · GERCOR - Multidisciplinary Oncology Cooperative Group (1) · J. W. A. Burger (1) · National Cancer Center Hospital East (1) · Sir Run Run Shaw Hospital (1) · Sun Yat-sen University (1)
Germany (4) · China (3) · France (3) · Japan (3) · Netherlands (3) · Argentina (2) · Australia (2) · Belgium (2) · Brazil (2) · Canada (2) · Chile (2) · India (2) · Italy (2) · Mexico (2) · Poland (2)
Dominik Modest, Prof. Dr. (1) · Dominik Modest, Prof. Dr. med. (1) · Jacobus WA Burger, Prof. dr. (1) · Peirong Ding, M.D. (1) · Pim Burger, MD (1) · Thierry Andre, MD (1)
PMID 29620995, PMID 32167864, PMID 35366831, PMID 36306483, PMID 39889251, PMID 39903903, PMID 41857556, PMID 42151882
2025 (3), 2009 (1), 2023 (1)